AGT and influenza: For instance, biological αGal modification is not optimal on either egg-derived influenza vaccines, or insect cell-based products, such as Flublok®, since their intrinsic N-glycosylation patterns lack the αGT substrate[30], i.e. terminal galactose residues, or the loss of glycosylation site during adaption [31], when compared to mammalian complex N-glycosylation [30].